New VEGF antagonists as possible therapeutic agents in vascular disease

Expert Opin Investig Drugs. 2008 Sep;17(9):1301-14. doi: 10.1517/13543784.17.9.1301.

Abstract

Background: In this review we provide the reader with an analysis of the importance of VEGF in modulating the angiogenic process in vascular diseases.

Objectives: We have described the key role of VEGF in the development of the major angiogenic diseases including ocular retinopathies, solid tumour growth and atherosclerotic plaque development.

Methods: Following a brief description of the disease, a detailed literature review of the mechanisms through which VEGF induces promotion of neovascularisation and current anti-VEGF therapies is provided for the reader.

Results/conclusions: Current and future potential clinical therapies are discussed in particular concerning our thoughts on future directives involving adenoviral-mediated gene targeting, nanotechnology and combinational therapies.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / chemistry
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Atherosclerosis / drug therapy
  • Atherosclerosis / metabolism
  • Eye Diseases / drug therapy
  • Eye Diseases / metabolism
  • Humans
  • Neoplasms / blood supply
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neovascularization, Pathologic / drug therapy
  • Vascular Endothelial Growth Factors / antagonists & inhibitors*
  • Vascular Endothelial Growth Factors / metabolism

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factors